Compounds point the way to cancer’s dependencies: Public portal launched to identify therapeutic sensitivities... http://t.co/fopdsnDQcf
— Broad Institute (@broadinstitute) August 29, 2013
Precision Medicine will need to get out of the pharma silo that is based on symptoms
Welcome to the digital era of biology (and to this modest blog I started in early 2005).
To cure many diseases, like cancer or cystic fibrosis, we will need to target genes (mutations, for ex.), not organs! I am convinced that the future of replacement medicine (organ transplant) is genomics (the science of the human genome). In 10 years we will be replacing (modifying) genes; not organs!
Anticipating the $100 genome era and the P4™ medicine revolution. P4 Medicine (Predictive, Personalized, Preventive, & Participatory): Catalyzing a Revolution from Reactive to Proactive Medicine.
After low-cost airlines (Ryanair, Easyjet ...) comes "low-cost" participatory medicine. Some of my readers have recently christened this long-lasting, clumsy attempt at e-writing of mine "THE LOW-COSTE INNOVATION BLOG". I am an early adopter of scientific MOOCs. My name's Catherine Coste. I've earned myself four MIT digital diplomas: 7.00x, 7.28x1, 7.28.x2 and 7QBWx. Instructor of 7.00x: Eric Lander PhD.
Upcoming books: Airpocalypse, a medical thriller (action taking place in Beijing) 2017; Jesus CRISPR Superstar, a sci-fi -- French title: La Passion du CRISPR (2018).
I love Genomics. Would you rather donate your data, or... your vital organs?
Audio files on this blog are Windows files ; if you have a Mac, you might want to use VLC (http://www.videolan.org) to read them.
Concernant les fichiers son ou audio (audio files) sur ce blog : ce sont des fichiers Windows ; pour les lire sur Mac, il faut les ouvrir avec VLC (http://www.videolan.org).
CTRP portal: a critical resource for advancing the discovery of potential cancer drugs matched to the patient populations most likely to benefit from them
"The Broad Institute’s Center for the Science of Therapeutics today announced the launch of its Cancer Therapeutics Response Portal (CTRP) – a critical resource for advancing the discovery of potential cancer drugs matched to the patient populations most likely to benefit from them. The portal, which will serve as a public resource for researchers worldwide, contains more than 70,000 connections between compound sensitivities and genetic or lineage features of cancer cell lines – creating a dataset that researchers can use to look for therapeutically exploitable vulnerabilities in different cancer types." (Source)